血管紧张素转换酶基因I/D多态性与埃他卡林抗高血压临床疗效之间的相关性

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (9): 961-966.

• 基础研究 • 下一篇

血管紧张素转换酶基因I/D多态性与埃他卡林抗高血压临床疗效之间的相关性

段瑞峰¹, 崔文玉², 高红岩³, 王小佩³, 胡胜凯³, 刘卫², 汪海^1,2,3

¹军事医学科学院卫生学环境医学研究所,北京 100850;
²军事医学科学院毒物药物研究所,北京 100850;
³北京赛德维康医药研究院,北京 100039

收稿日期:2010-08-20 修回日期:2010-09-14 出版日期:2010-09-26 发布日期:2020-09-17
通讯作者: 汪海,男,博士,研究员,博士生导师,研究方向:特殊环境医学和分子心血管药理学。Tel: 010-66932651, E-mail: wh@nic.bmi.ac.cn
作者简介:段瑞峰,男,博士,助理研究员,研究方向:特殊环境医学和药物基因组学。Tel: 022-84655427, E-mail: duanruifeng6@126.com
基金资助:
国家重大科技专项军特药保密专项(2008ZXJ09004-018)

Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population

DUAN Rui-feng¹, CUI Wen-yu², GAO Hong-yan³, WANG Xiao-pei³, HU Sheng-kai³, LIU Wei², WANG Hai^1,2,3

¹Department of Environmental Medicine, Institute of Health and Environmental Medicine;
²Department of Cardiovascular Pharmacology, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China;
³Thadweik Acodemy of Medicine, Beijing 100039, China

Received:2010-08-20 Revised:2010-09-14 Online:2010-09-26 Published:2020-09-17

摘要/Abstract

摘要： 目的: 研究汉族高血压人群血管紧张素转换酶(angiotensin converting enzyme, ACE)基因插入/缺失(I/D)多态性与埃他卡林临床疗效的关系。方法: 对162例汉族原发性高血压(EH)患者给予埃他卡林8周治疗,并进行ACE基因I/D多态性分析。结果: 162例汉族高血压患者ACE基因I/D多态性分型结果为:II∶ID∶DD(0.401∶0.463∶0.136)。埃他卡林治疗前收缩压(SBP)和舒张压(DBP)分别是(153±13) mm Hg　和(100±4) mm Hg。各基因型组患者在药物治疗前SBP和DBP 的特点是DD基因型组的SBP显著高于II和ID基因型组(P<0.05),而3种基因型组的DBP比较相近(P>0.05)。治疗后SBP和DBP分别是(142±13) mm Hg　和(89±9)　mm Hg。治疗后II基因型组患者的ΔDBP显著大于ID组的ΔDBP(P<0.05)。治疗后血压较治疗前血压降低(P<0.001)。162例汉族高血压患者埃他卡林治疗8周后临床有效率为66.67%。II基因型组的总降压有效率(75.38%)比ID基因型组的总降压有效率(58.67%)高(P<0.05)。结论: 埃他卡林是新型有效降压药物,II基因型患者对埃他卡林的降压反应较好。

关键词: 埃他卡林, 高血压, 血管紧张素转换酶, 基因多态性

Abstract: AIM: To study the correlation between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and the clinical efficacy of iptakalim in a Chinese Han hypertensive population.METHODS: The ACE I/D polymorphism of 162 Chinese Han hypertensive patients treated with iptakalim for 8 weeks was determined by the polymerase chain reaction technique.RESULTS: Among the 162 cases of hypertensive patients, the frequencies of II, ID, and DD were 40.1%, 46.3%, and 13.6%, respectively. The pretreatment SBP and DBP were (153±13) mm Hg and (100±4) mm Hg, respectively. The pretreatment DBP were not different in the three groups, while the pretreatment SBP were larger in patients with the DD genotype than those with the II and ID genotypes (P<0.05). The posttreatment SBP and DBP were (142±13) mm Hg and (89±9) mm Hg, respectively. The changes of SBP and DBP by iptakalim were significant (P<0.001). The posttreatment SBP were similar in the three groups, while a greater decrease in DBP was observed in patients with the II genotype than those with the ID genotype (P<0.05). The clinical efficacy was 66.67% after iptakalim administration in 162 patients. The clinical efficacy of the II genotype group (75.38%) was higher than that of the ID genotype group (58.67%) (P<0.05).CONCLUSION: Iptakalim is a new and effective antihypertensive drug. The patients with the genotype II have better clinical efficacy.

Key words: Iptakalim, Hypertension, ACE, Gene polymorphism

中图分类号:

R969

段瑞峰, 崔文玉, 高红岩, 王小佩, 胡胜凯, 刘卫, 汪海. 血管紧张素转换酶基因I/D多态性与埃他卡林抗高血压临床疗效之间的相关性[J]. 中国临床药理学与治疗学, 2010, 15(9): 961-966.

DUAN Rui-feng, CUI Wen-yu, GAO Hong-yan, WANG Xiao-pei, HU Sheng-kai, LIU Wei, WANG Hai. Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 961-966.

参考文献

[1] Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels[J]. J Clin Invest, 1990,86(4):1343-1346.
[2] Yukiko N, Tetsuya O, Hiroyuki H, et al. DD genotype of the angiotensin I-converting enzyme gene is a risk factor for early onset of essential hypertension in Japanese patients[J]. J Lab Clin Med,1998,131(6):502-506.
[3] 李冬青,王希柱,杨国强,等. ACE基因I/D和AT1R基因A1166C多态性与氢氯噻嗪降压疗效的相关性研究[J]. 山东医药,2008,48(4):19-21.
[4] 皮林,华琦,陈彪. ACE基因多态性与福辛普利降压疗效的关系[J]. 同济大学学报:医学版, 2007,28(6):30-33.
[5] Jiang X, Sheng HH, Lin G, et al. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment[J]. Chin Med J (Engl),2007,120(9):782-786.
[6] Moraes CF, Souza ER, Souza VC, et al. A common polymorphism in the renin angiotensin system is associated with differential outcome of antihypertensive pharmacotherapy prescribed to Brazilian older women[J]. Clin Chim Acta, 2008,396(1/2):70-75.
[7] Wang H, Long CL, Zhang YL. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension[J]. J Pharmacol Exp Ther, 2005,312(3):1326-1333.
[8] Xue H, Zhang YL, Liu GS, et al. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats[J]. J Pharmacol Exp Ther,2005,315(2):501-509.
[9] Wang H, Tang Y, Wang L, et al. ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives[J]. Curr Med Chem, 2007,14(2):133-155.
[10] Prasad A, Narayanan S, Waclawiw MA, et al. The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity[J]. J Am Coll Cardiol, 2000, 36(5):1579-1586.
[11] Darbar D, Motsinger AA, Ritchie MD, et al. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation[J]. Heart Rhythm, 2007,4(6):743-749.
[12] Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease[J]. N Engl J Med, 1995,332(11):706-711.
[13] 刘国仗,胡大一,陶萍,等. 心血管药物临床试验评价方法的建议[J]. 中华心血管病杂志,1998,26(1):5-11.
[14] 范秀珍,郭歆,王华杰,等. MDR1基因C3435T多态性对替米沙坦稳态血药浓度及降压疗效的影响[J]. 中国临床药理学与治疗学,2009,14(6):670-676.
[15] 王谷亮,韩战营. 血管紧张素转换酶基因插入／缺失多态性检测方法的研究[J]. 中华心血管病杂志,2001,29(4):239-239.
[16] 刘长云,周建光,黄亚莉,等. 血管紧张素转换酶基因多态性与高血压的关系[J]. 中华航海医学与高气压医学杂志,2006,13(5):290-291.
[17] Zhang S, Mao G, Zhang Y, et al. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension[J]. Clin Ther, 2005, 27(11):1774-1784.
[18] Trotta R, Donati MB, Iacoviello L. Trends in pharmacogenomics of drugs acting on hypertension[J]. Pharmacol Res, 2004, 49(4):351-356.
[19] Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance[J]. Pharmacogenomics, 2009, 10(8):1295-1307.
[20] 姜远英. 药物基因组学[M]. 北京:人民卫生出版社,2006:9.
[21] Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment[J]. 2006,44(2):107-118.

血管紧张素转换酶基因I/D多态性与埃他卡林抗高血压临床疗效之间的相关性

Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[5]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[6]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[7]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[8]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[9]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[10]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[11]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[12]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[13]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[14]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[15]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.